Advertisement

Science-Business eXchange

, Volume 6, Issue 42, pp 1181–1181 | Cite as

Personal factors

  • Chris Cain
Article
  • 47 Downloads

Abstract

A multi-institute team collaborating with the FDA has determined why patients with a form of severe hemophilia rarely develop neutralizing antibodies against factor VIII replacement therapy. The group is developing an algorithm to predict the likelihood of antibody development against other recombinant protein–based therapies.

Copyright information

© Nature Publishing Group 2013

Authors and Affiliations

  • Chris Cain

There are no affiliations available

Personalised recommendations